Compare AU

Compare DGCE vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Dimensional Global Core Equity Trust Unhedged - Active ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DGCE and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

DGCE

DRUG

Popularity

Low

Low

Pearlers invested

14

63

Median incremental investment

$2,588.59

$990.50

Median investment frequency

Monthly

Monthly

Median total investment

$4,982.55

$1,910.37

Average age group

26 - 35

26 - 35


Key Summary

DGCE

DRUG

Strategy

DGCE.AX was created on 2006-12-05 by Dimensional. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to provide long-term capital growth by gaining exposure to a diversified portfolio of securities associated with approved developed markets (excluding Australia), with increased emphasis on higher expected return securities relative to a Market Capitalisation Weighted portfolio.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Dimensional Global Core Equity Trust Unhedged - Active ETF (100 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.36 %

0.57 %


Key Summary

DGCE

DRUG

Issuer

Dimensional

BetaShares

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.36 %

0.57 %

Price

$28.15

$8.29

Size

N/A

$182.401 million

10Y return

N/A

N/A

Annual dividend/ distribution yield (5Y)

0.56 %

1.90 %

Market

ASX

ASX

First listed date

12/11/2023

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

DGCE

DRUG

Popularity

Low

Low

Pearlers invested

14

63

Median incremental investment

$2,588.59

$990.50

Median investment frequency

Monthly

Monthly

Median total investment

$4,982.55

$1,910.37

Average age group

26 - 35

26 - 35


Pros and Cons

DGCE

DRUG

Pros

  • Lower management fee

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

  • Higher management fee

DGCE

DRUG

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home